Novartis has terminated EPIK-O, a global Phase 3 trial testing whether pairing the PI3K-alpha inhibitor alpelisib (Piqray) with the PARP inhibitor olaparib (Lynparza) could outperform standard chemotherapy in women with one of the hardest-to-treat ovarian cancers. The posted results show the combination missed its primary endpoint, and the registry lists the reason for stopping as “Sponsor Decision.”

The rationale was biologically appealing. In platinum-resistant or platinum-refractory high-grade serous ovarian cancer without a germline BRCA mutation, single-agent PARP inhibition has limited reach; preclinical work had suggested that PI3K blockade might sensitize these tumors to olaparib. EPIK-O randomized 358 such patients 1:1 to alpelisib plus olaparib (180 patients) or to investigator’s choice of paclitaxel or pegylated liposomal doxorubicin (178 patients), in an open-label, active-controlled design.

The combination did not separate from chemotherapy

On the primary endpoint — progression-free survival by blinded independent review using RECIST 1.1 — the two arms were statistically indistinguishable, and the trend favored chemotherapy. Median progression-free survival was 3.6 months with alpelisib-olaparib versus 3.9 months with chemotherapy. The stratified hazard ratio was 1.142 (95% CI 0.882–1.478), with a log-rank p-value of 0.84.

A hazard ratio above 1, with a confidence interval straddling unity, means the experimental combination showed no progression-free survival benefit — and if anything trended worse — than standard single-agent chemotherapy.

Secondary efficacy offered no rescue. The confirmed overall response rate was 15.6% (95% CI 10.6–21.7) in the combination arm versus 13.5% (95% CI 8.8–19.4) with chemotherapy — overlapping intervals and no meaningful gain.

Safety pointed the other way. In the safety population (180 combination, 164 chemotherapy), 92 patients (51.1%) on alpelisib-olaparib had a serious adverse event, versus 50 patients (30.5%) on chemotherapy. On-treatment deaths numbered 26 in the combination arm and 7 in the chemotherapy arm. The combination thus carried more harm without offsetting efficacy.

EPIK-O joins a long line of attempts to extend PARP-inhibitor benefit beyond BRCA-mutated, platinum-sensitive disease through combination strategies. For platinum-resistant high-grade serous ovarian cancer without a germline BRCA mutation — a setting where outcomes remain poor and chemotherapy remains the backbone — this particular hypothesis did not hold. These are registry-posted results; a peer-reviewed publication with full subgroup and overall-survival data would add context.